Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The United States radiation medical countermeasures (MCM) programme for radiological and nuclear incidents has been focusing on developing mitigators for the acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE), and biodosimetry technologies to provide radiation dose assessments for guiding treatment. Because a nuclear accident or terrorist incident could potentially expose a large number of people to low to moderate doses of ionising radiation, and thus increase their excess lifetime cancer risk, there is an interest in developing mitigators for this purpose. This article discusses the current status, issues, and challenges regarding development of mitigators against radiation-induced cancers. The challenges of developing mitigators for ARS include: the long latency between exposure and cancer manifestation, limitations of animal models, potential side effects of the mitigator itself, potential need for long-term use, the complexity of human trials to demonstrate effectiveness, and statistical power constraints for measuring health risks (and reduction of health risks after mitigation) following relatively low radiation doses (<0.75 Gy). Nevertheless, progress in the understanding of the molecular mechanisms resulting in radiation injury, along with parallel progress in dose assessment technologies, make this an opportune, if not critical, time to invest in research strategies that result in the development of agents to lower the risk of radiation-induced cancers for populations that survive a significant radiation exposure incident.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 1×
“This is a useful framework and as the understanding of the underlying molecular mechanisms of carcinogenesis increases, these steps and new potential areas of mitigation will be better defined (Gillies et al 2012, McCormick 1999, Vogelstein et al 2013).”
BackgroundCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“…numerous human cancer prevention trials but many of these trials were stopped when results from the Adenomatous Polyp Prevention on Vioxx (APPROVe) (Bresalier et al 2005) and Adenoma Prevention with Celecoxib (Bertagnolli et al 2006) trials indicated that COX-2 inhibitors were associated with…”
BackgroundThe Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970 · cited 1×
“Biomarker-based treatment decisions may eventually drive personalised medicine (Hamburg and Collins 2010), however, the definitive utility of these biomarkers requires conducting large RCTs for validation.”
BackgroundKlein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970 · cited 1×
“There are several drugs that are used as human cancer chemopreventive or ‘risk reduction’ products, such as exemestane for breast cancer (Goss et al 2011) and aspirin in several common cancers (Rothwell et al 2011).”
BackgroundMethionine restriction increases blood glutathione and longevity in F344 rats
Richie, J. P., Leutzinger, Y., Parthasarathy, S., Maixoy, V., Orentreich, N., & Zimmerman, J. A. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.15.8001743 · Cited by 363
Huang, H.-Y., Caballero, B., Chang, S., Alberg, A. J., Semba, R. D., Schneyer, C. R., Wilson, R. F., Cheng, T.-Y., Vassy, J., Prokopowicz, G., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-5-200609050-00135 · Cited by 243
Radiation-induced Thyroid Cancer—What's New?
Boice, J. D. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji151 · Cited by 76
Self-citation
Cited by
Inaniwa, T., Kanematsu, N., Matsufuji, N., Kanai, T., Shirai, T., Noda, K., Tsuji, H., Kamada, T., & Tsujii, H. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/8/3271 · Cited by 263
DiCarlo, A. L., Carnell, L. S., Rios, C. I., & Prasanna, P. G. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.06.004 · Cited by 5
Self-citation
Metadata
- Authors
- Yoo, S. S., Jorgensen, T. J., Kennedy, A. R., Boice Jr, J. D., Shapiro, A., Hu, T. C.-C., Moyer, B. R., Grace, M. B., Kelloff, G. J., Fenech, M., Prasanna, P. G. S., & Coleman, C. N.
- Venue
- Journal of Radiological Protection
- Publisher
- IOP Publishing
- Published
- 2014-04-14
- Volume
- 34
- Issue
- 2
- Pages
- R25-R52
- ISSN
- 0952-4746 (ISSN-L)
- 1361-6498
- OpenAlex
- W2010962051
- Cited by
- 221
- References
- 10
- FWCI
- 33.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development. https://app.cochat.ai/papers/10.1088/0952-4746/34/2/r25
- The paper
- Yoo, S. S., Jorgensen, T. J., Kennedy, A. R., Boice Jr, J. D., Shapiro, A., Hu, T. C.-C., Moyer, B. R., Grace, M. B., Kelloff, G. J., Fenech, M., Prasanna, P. G. S., & Coleman, C. N. (2014). Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development. Journal of Radiological Protection. https://doi.org/10.1088/0952-4746/34/2/r25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.